DNA Methylation pp 165-174

Part of the Methods in Molecular Biology book series (MIMB, volume 507)

5′-Azacytidine Expression Arrays

  • Paul Cairns


Epigenetic silencing of a gene can be reversed, resulting in reactivation of expression, by drugs such as the DNA methylation inhibitor 5-Aza-2′-deoxycytidine (5Aza-dC, azacytidine). This drug is added to cell culture media and is incorporated into the new strand during DNA replication in the cell. 5Aza-dC forms a covalent complex with the active sites of the DNA methyltransferase, depleting methyltransferase activity, which results in generalized demethylation. Until recently, global analyses of gene methylation in cancer cells were largely restricted to array or gel-based comparisons of the methylation status of CpG islands between normal and tumor cell DNA. An expression microarray-based screen has the advantage of a more genome-wide analysis with a better gene annotation and, coupled with a reactivation strategy, has the further advantage that it should preferentially identify reexpression of epigenetically silenced genes over methylated CpG islands that do not influence transcription. However, the direct reactivation of methylated genes, as well as secondary effects of azacytidine treatment, can lead to a cascade of deregulation in downstream unmethylated gene expression. A validation strategy is therefore the key for efficient identification of genes methylated in the wild-type cultured tumor cells. An azacytidine-based reactivation approach can only be used on cell lines so validation should include analysis of primary tumors. The potential of this approach for the identification of new hypermethylated genes and pathways has been demonstrated in bladder, colorectal, esophageal, and most other cancer types.


Azacytidine expression array epigenetic reactivation tumor suppressor gene CpG island demethylation tumor cell lines 


  1. 1.
    Jones, P. A., Baylin, S. B. (2007) The epigenomics of cancer. Cell 128, 683–692.CrossRefPubMedGoogle Scholar
  2. 2.
    Costello, J. F., Frühwald, M. C., Smiraglia, D. J., et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 25, 132–138.CrossRefGoogle Scholar
  3. 3.
    Sjoblom, T., Jones, S., Wood, L. D., et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274.CrossRefPubMedGoogle Scholar
  4. 4.
    Suzuki, H., Gabrielson, E., Chen, W., et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31, 141–149.CrossRefPubMedGoogle Scholar
  5. 5.
    Ibanez de Caceres, I., Dulaimi, E., Hoffman, A. M., et al. (2006) Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 66, 5021–5028.CrossRefGoogle Scholar
  6. 6.
    Liang, G., Gonzales, F. A., Jones, P. A., et al. (2002) Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 62, 961–966.PubMedGoogle Scholar
  7. 7.
    Yamashita, K., Upadhyay, S., Osada, M., et al. (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485–495.CrossRefPubMedGoogle Scholar
  8. 8.
    Tusher, V. G., Tibshirani, R., Chu, G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116–5121.CrossRefPubMedGoogle Scholar
  9. 9.
    Takai, D., Jones, P. A. (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99, 3740–3745.CrossRefPubMedGoogle Scholar
  10. 10.
    Smiraglia, D. J., Rush, L. J., Frühwald, M. C., et al. (2001) Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 10, 1413–1419.CrossRefPubMedGoogle Scholar
  11. 11.
    Cameron, E. E., Bachman, K. E., Myohanen, S., et al. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21, 1037.CrossRefGoogle Scholar
  12. 12.
    Shames, D. S., Girard, L., Gao, B., et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3, e486.CrossRefPubMedGoogle Scholar
  13. 13.
    Dammann, R., Li, C., Yoon, J.-H., et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25, 315–319.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Paul Cairns
    • 1
  1. 1.Department of Surgical Oncology, Fox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations